公开(公告)号：WO2015084936A1

公开(公告)日：2015-06-11

申请号：PCT/US2014/068333

申请日：2014-12-03

申请人： THE SCRIPPS RESEARCH INSTITUTE ,  FENG, Yangbo ,  LOGRASSO, Philip ,  ZHENG, Ke ,  PARK, Chul Min

发明人： FENG, Yangbo ,  LOGRASSO, Philip ,  ZHENG, Ke ,  PARK, Chul Min

IPC分类号： A01N43/56

CPC分类号： C07D231/40 ,  C07D231/54 ,  C07D239/47 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The present invention is directed to modulators, such as inhibitors, of JNK isoform 2 (JNK2) or isoform 3 (JNK3) comprising compounds of formula (I) or formula (II) as described herein. Compounds of the invention can be used for treatment of a medical disorder in a patient wherein modulation of JNK3 is medically indicated, such as when the disorder is Parkinsons disease (PD) Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), myocardial infarction (MI), glaucoma, obesity, diabetes, cancer, rheumatoid arthritis, fibrotic disease, pulmonary fibrosis, kidney disease, liver inflammation, Crohns disease, hearing loss, Prader Willi syndrome, or a condition where modification of feeding behavior is medically indicated.

摘要翻译： 本发明涉及包含本文所述的式（I）或式（II）化合物的JNK同种型2（JNK2）或同种型3（JNK3）的调节剂，例如抑制剂。 本发明的化合物可用于治疗患有医学上指示JNK3调节的患者的医学病症，例如当疾病是帕金森病（PD）阿尔茨海默病（AD），亨廷顿病（HD），肌萎缩性侧索硬化症 （ALS），多发性硬化症（MS），心肌梗塞（MI），青光眼，肥胖症，糖尿病，癌症，类风湿性关节炎，纤维化疾病，肺纤维化，肾脏疾病，肝脏炎症，克罗恩病，听力损失，Prader Willi综合征或 在医疗上指示进食行为改变的条件。

公开(公告)号：WO2011162562A2

公开(公告)日：2011-12-29

申请号：PCT/KR2011/004607

申请日：2011-06-24

申请人： KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY ,  LG LIFE SCIENCES LTD. ,  LEE, Sun Kyung ,  SONG, Jong Whan ,  LIM, Dong Chul ,  CHO, Woo Young ,  PARK, Chul Min

发明人： LEE, Sun Kyung ,  SONG, Jong Whan ,  LIM, Dong Chul ,  CHO, Woo Young ,  PARK, Chul Min

IPC分类号： C07D405/06 ,  C07D317/72 ,  A61K31/443 ,  A61P9/10

CPC分类号： A61K31/443 ,  C07D213/30 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

摘要： The present invention relates to the new [6+5] fused bicycle derivatives, pharmaceutically acceptable salts or isomers thereof, processes for preparing the same, and pharmaceutical compositions comprising the same. The [6+5] fused bicycle derivatives can antagonize the thrombin receptor and thus may be effectively used for the treatment and prevention of thrombus, platelet aggregation, atherosclerosis, restenosis, blood coagulation, hypertension, arrhythmia, angina pectoris, heart failure, inflammation and cancer when used alone or with other cardiovascular agents.

摘要翻译： 本发明涉及新的[6 + 5]稠合自行车衍生物，其药学上可接受的盐或异构体，其制备方法和包含其的药物组合物。 [6 + 5]融合自行车衍生物可以拮抗凝血酶受体，因此可以有效地用于治疗和预防血栓，血小板聚集，动脉粥样硬化，再狭窄，凝血，高血压，心律失常，心绞痛，心力衰竭，炎症和 当单独使用或与其他心血管药物一起使用时。

公开(公告)号：WO2008004716A1

公开(公告)日：2008-01-10

申请号：PCT/KR2006/002631

申请日：2006-07-05

申请人： KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY ,  SEONG, Churlmin ,  PARK, Nosang ,  CHOI, Jinil ,  PARK, Chul Min ,  PARK, Wookyu ,  KONG, Jaeyang

发明人： SEONG, Churlmin ,  PARK, Nosang ,  CHOI, Jinil ,  PARK, Chul Min ,  PARK, Wookyu ,  KONG, Jaeyang

IPC分类号： C07D401/04 ,  C07D401/14 ,  A61K31/415 ,  A61P25/28

CPC分类号： C07D239/96 ,  C07D401/06 ,  C07D405/06

摘要： Disclosed herein are novel substituted-lH-quinazoline-2,4-dione derivatives, a preparation method thereof, and a pharmaceutical composition containing the same. The novel substituted- lH-quinazoline-2,4-dione derivatives are excellent in binding affinity and selectivity for 5-HT6 receptors over other receptors, inhibit serotonin(5-HT)-stimulated cAMP accumulation, and disrupt apomorphine(2 mg/kg, i.p.)-induced hyperactivity in rats. Thanks to these effects, the derivatives are useful in the treatment of 5-HT6 receptor-related central nervous system diseases.

摘要翻译： 本文公开了新的取代的1H-喹唑啉-2,4-二酮衍生物，其制备方法和含有该取代基的喹唑啉-2,4-二酮衍生物的药物组合物。 新型取代的1H-喹唑啉-2,4-二酮衍生物对5-HT6受体的结合亲和力和其他受体的选择性优于其他受体，抑制5-羟色胺（5-HT）刺激的cAMP积累，并破坏阿扑吗啡（2mg / kg ，ip）诱导大鼠活动过度。 由于这些效果，衍生物可用于治疗5-HT6受体相关的中枢神经系统疾病。

公开(公告)号：WO2005117430A1

公开(公告)日：2005-12-08

申请号：PCT/KR2005/000203

申请日：2005-01-25

申请人： SAMSUNG ELECTRONICS CO., LTD. ,  HUR, Jean ,  PARK, Chul-Min

发明人： HUR, Jean ,  PARK, Chul-Min

IPC分类号： H04N5/74

CPC分类号： H04N9/3114 ,  G03B21/16 ,  G03B33/08 ,  H04N9/3144

摘要： A projection television including a light source emitting light; and color wheel including a plurality of color filters provided in front of the light source and transmitting the light from the light source, a driver rotatably driving the plurality of color filters, and a supporter having a first side coupled to the driver and a second side coupled to the plurality of color filters so as to rotatably support the plurality of color filters, the driver being provided in a center portion of the color wheel, the plurality of color filters are provided around an edge of the color wheel being spaced from the driver, and a heat barrier being provided between the driver and the plurality of color filters to prevent heat generated due to the plurality of color filters from being transmitted to the driver. Thus, a projection television having a color filter absorbing heat generated from the light source disposed separately from the driver so as to prevent functional quality of the color wheel from being degraded due to the heat is provided.

摘要翻译： 包括发光光源的投影电视机; 以及色轮，包括设置在光源前面的多个滤色器，并且透射来自光源的光，可旋转地驱动多个滤色器的驱动器，以及具有连接到驱动器的第一侧的支撑件和与驱动器连接的第二侧 耦合到所述多个滤色器以便可旋转地支撑所述多个滤色器，所述驱动器设置在所述色轮的中心部分中，所述多个滤色器设置在所述色轮的与所述驱动器间隔开的边缘周围 并且在所述驱动器和所述多个滤色器之间设置有热障，以防止由于所述多个滤色器而产生的热量被传递到所述驱动器。 因此，提供了一种投影电视，其具有吸收从与驱动器分开设置的光源产生的热量的滤色器，以防止色轮的功能质量由于热而劣化。

公开(公告)号：WO1996032141A1

公开(公告)日：1996-10-17

申请号：PCT/KR1996000052

申请日：1996-04-12

申请人： SAM YANG CO., LTD. ,  LEE, Hun, Han ,  CHO, Joon, Woong ,  KIM, Choul, Young ,  SONG, Jin, Deog ,  PARK, Chul, Min ,  YOON, Hye, Jeong ,  YEO, Yoon ,  PAICK, Jae, Seung ,  PAI, Chaul, Min

发明人： SAM YANG CO., LTD.

IPC分类号： A61L15/44

CPC分类号： A61K9/703 ,  A61F5/41 ,  A61F6/04 ,  A61K9/0034 ,  A61K9/7092 ,  Y10S602/901

摘要： The present invention is to provide a method and a transdermal drug delivery device for treating erectile dysfunction which comprises a patch (100) containing pharmaceutically active ingredient and being directly applied to the male glans and its support (200) and the rings (30) for compressing the base part of the penis to aid the erection. The patch according to the present invention may be divided into two types, i.e. a cylinder type patch and a multi-reservoir type patch. The transdermal drug delivery patch device of the present invention is painless and safely to use and may be effectively produced and maintained erection of the penis without the adverse side effects and with a high degree of patient acceptability in the case of male impotence.

摘要翻译： 本发明提供一种用于治疗勃起功能障碍的方法和透皮药物递送装置，其包含含有药物活性成分的贴剂（100），并直接施用于雄性龟头及其支持体（200）和环（30），用于 压缩阴茎的基部以辅助勃起。 根据本发明的贴片可以分为两种类型，即圆柱型贴片和多储器型贴片。 本发明的透皮药物递送贴片装置是无痛且安全使用的，并且可以有效地产生和维持阴茎的勃起而没有不利的副作用，并且在男性阳the的情况下具有高度的患者可接受性。

公开(公告)号：WO2011162562A3

公开(公告)日：2012-05-31

申请号：PCT/KR2011004607

申请日：2011-06-24

申请人： KOREA RES INST CHEM TECH ,  LG LIFE SCIENCES LTD ,  LEE SUN KYUNG ,  SONG JONG WHAN ,  LIM DONG CHUL ,  CHO WOO YOUNG ,  PARK CHUL MIN

发明人： LEE SUN KYUNG ,  SONG JONG WHAN ,  LIM DONG CHUL ,  CHO WOO YOUNG ,  PARK CHUL MIN

IPC分类号： C07D405/06 ,  A61K31/443 ,  A61P9/10 ,  C07D317/72

CPC分类号： A61K31/443 ,  C07D213/30 ,  C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06

摘要： The present invention relates to the new [6+5] fused bicycle derivatives, pharmaceutically acceptable salts or isomers thereof, processes for preparing the same, and pharmaceutical compositions comprising the same. The [6+5] fused bicycle derivatives can antagonize the thrombin receptor and thus may be effectively used for the treatment and prevention of thrombus, platelet aggregation, atherosclerosis, restenosis, blood coagulation, hypertension, arrhythmia, angina pectoris, heart failure, inflammation and cancer when used alone or with other cardiovascular agents.

摘要翻译： 本发明涉及新的[6 + 5]稠合自行车衍生物，其药学上可接受的盐或异构体，其制备方法和包含其的药物组合物。 [6 + 5]融合自行车衍生物可以拮抗凝血酶受体，因此可有效地用于治疗和预防血栓，血小板聚集，动脉粥样硬化，再狭窄，凝血，高血压，心律失常，心绞痛，心力衰竭，炎症和 当单独使用或与其他心血管药物一起使用时。

公开(公告)号：WO2009125923A2

公开(公告)日：2009-10-15

申请号：PCT/KR2009/000786

申请日：2009-02-19

申请人： KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY ,  SEONG, Churlmin ,  PARK, Chul Min ,  KIM, Soyoung ,  PARK, Wookyu ,  PARK, Nosang

发明人： SEONG, Churlmin ,  PARK, Chul Min ,  KIM, Soyoung ,  PARK, Wookyu ,  PARK, Nosang

IPC分类号： C07D401/14

CPC分类号： C07D401/14 ,  C07D401/12 ,  C07D403/12

摘要： Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT 2c receptors, act selectively on the 5-HT 2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT 2c receptors.

摘要翻译： 本文公开了一种新的吲哚羧酸双吡啶甲酰胺衍生物，其制备方法，以及用于预防或治疗肥胖症，泌尿疾病和CNS疾病的组合物，其包含其作为活性成分。 由于根据本发明的吲哚羧酸双吡啶基甲酰胺衍生物对5-HT 2c受体具有高亲和力，因此选择性地作用于5-HT 2c受体，所述衍生物很少 有其他受体引起的不良反应。 由于衍生物有效地抑制5-羟色胺活性，它们可用于治疗或预防肥胖; 泌尿失调如尿失禁，早泄，勃起功能障碍和前列腺增生; 与5-HT 2c受体有关的CNS障碍如抑郁症，焦虑症，忧虑症，恐慌症，癫痫症，强迫症，偏头痛，睡眠障碍，戒断药物滥用，阿尔茨海默病和精神分裂症

公开(公告)号：WO2009125923A3

公开(公告)日：2009-12-03

申请号：PCT/KR2009000786

申请日：2009-02-19

申请人： KOREA RESERACH INST OF CHEMICA ,  SEONG CHURLMIN ,  PARK CHUL MIN ,  KIM SOYOUNG ,  PARK WOOKYU ,  PARK NOSANG

发明人： SEONG CHURLMIN ,  PARK CHUL MIN ,  KIM SOYOUNG ,  PARK WOOKYU ,  PARK NOSANG

IPC分类号： C07D401/14

CPC分类号： C07D401/14 ,  C07D401/12 ,  C07D403/12

摘要： Disclosed herein are a new indole carboxylic acid bispyridyl carboxamide derivative, a preparation method thereof, and a composition for prevention or treatment of obesity, urinary disorders, and CNS disorders, containing the same as an active ingredient. Because the indole carboxylic acid bispyridyl carboxamide derivatives according to the present invention have high affinity for 5-HT2c receptors, act selectively on the 5-HT2c receptors, the derivatives rarely have adverse effects caused by other receptors. Because the derivatives effectively inhibit serotonin activity, they may be useful for treatment or prevention of obesity; urinary disorders such as urinary incontinence, premature ejaculation, erectile dysfunction, and prostatic hyperplasia; CNS disorders such as depression, anxiety, concern, panic disorder, epilepsy, obsessive-compulsive disorder, migraine, sleep disorder, withdrawal from drug abuse, Alzheimer's disease, and schizophrenia, associated with 5-HT2c receptors.

摘要翻译： 本文公开了一种新的吲哚羧酸双吡啶羧酰胺衍生物及其制备方法，以及用于预防或治疗肥胖，尿失调和CNS障碍的组合物，其含有活性成分。 因为根据本发明的吲哚羧酸双吡啶甲酰胺衍生物对5-HT 2C受体具有高亲和力，因此选择性地对5-HT 2C受体起作用，所以衍生物很少具有由其它受体引起的不良作用。 由于衍生物有效抑制5-羟色胺活性，因此可用于治疗或预防肥胖症; 尿失禁如尿失禁，早泄，勃起功能障碍和前列腺增生; 与5-HT2c受体相关的诸如抑郁症，焦虑症，忧虑症，惊恐障碍，癫痫症，强迫症，偏头痛，睡眠障碍，药物滥用戒断，阿尔茨海默病和精神分裂症等CNS疾病。

公开(公告)号：WO2007108569A1

公开(公告)日：2007-09-27

申请号：PCT/KR2006/001127

申请日：2006-03-28

申请人： KOREA RESERACH INSTITUTE OF CHEMICAL TECHNOLOGY ,  SEONG, Churlmin ,  CHOI, Jinil ,  PARK, Chul Min ,  PARK, Wookyu ,  KONG, Jaeyang ,  KANG, Sunhee ,  PARK, Chimin

发明人： SEONG, Churlmin ,  CHOI, Jinil ,  PARK, Chul Min ,  PARK, Wookyu ,  KONG, Jaeyang ,  KANG, Sunhee ,  PARK, Chimin

IPC分类号： C07D417/04

CPC分类号： C07D285/24

摘要： The present invention relates to compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones acting as a 5HT6 receptor antagonist, a preparation method thereof, and a pharmaceutical composition containing the same for treatment of the central nervous system disorders. The compounds of substituted-1,1-dioxo-benzo[1,2,4]thiadiazin-3-ones according to the present invention have excellent binding affinity for the 5HT6 receptor and excellent selectivity for the 5HT6 receptor over other receptors. Also, the compounds reverse a disruption of PPI by apomorphine and don't show rotatod deficit in mice. Therefore the compounds according to the present invention may be valuably used for treatment of a 5HT6 receptor relating disorders.

摘要翻译： 本发明涉及作为5HT6受体拮抗剂的取代-1,1-二氧代 - 苯并[1,2,4]噻二嗪-3-酮的化合物，其制备方法和含有该化合物的药物组合物，其用于治疗 中枢神经系统疾病。 根据本发明的取代的-1,1-二氧代 - 苯并[1,2,4]噻二嗪-3-酮的化合物对5HT6受体具有优异的结合亲和力，对5HT6受体的选择性优于其他受体。 此外，化合物反转了阿朴吗啡对PPI的破坏，并且在小鼠中不显示旋转异位缺陷。 因此，根据本发明的化合物可以有价值地用于治疗5HT6受体相关疾病。